Charles Gersbach | Scholars@Duke

Charles Gersbach
Rooney Family Associate Professor of Biomedical Engineering

Current Research Interests

Gene therapy, genomics and epigenomics, biomolecular and cellular engineering, regenerative medicine, and synthetic biology.

Current Appointments & Affiliations

Rooney Family Associate Professor of Biomedical Engineering, Biomedical Engineering, Pratt School of Engineering 2016
Associate Professor of Biomedical Engineering, Biomedical Engineering, Pratt School of Engineering 2015
Associate Professor of Orthopaedic Surgery, Orthopaedics, Orthopaedics 2015
Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2013
Affiliate of the Regeneration Next Initiative, Regeneration Next Initiative, Institutes and Centers 2016
Associate of the Duke Initiative for Science & Society, Duke Science & Society, Initiatives 2017

Contact Information

2353C CIEMAS, Durham, NC 27708
Box 90281, 136 Hudson Hall, Durham, NC 27708
charles.gersbach@duke.edu (919) 613-2147
Google Scholar
http://gersbach.bme.duke.edu/

Background
Education, Training, & Certifications
- Ph.D., Georgia Institute of Technology 2006
- B.S., Georgia Institute of Technology 2001
Duke Appointment History
- Assistant Professor of Orthopaedic Surgery, Orthopaedics, Orthopaedics 2013 - 2015
- Assistant Professor of Biomedical Engineering, Biomedical Engineering, Pratt School of Engineering 2009 - 2015
- Investigator in the Institute for Genome Sciences & Policy, Institutes and Centers, School of Medicine 2012 - 2014
- Assistant Research Professor of Biomedical Engineering, Biomedical Engineering, Pratt School of Engineering 2009
Recognition
In the News
- FEB 18, 2019 Pratt School of Engineering
  
  Single Genetic Editing Treatment Provides Long-Term Benefits in Mice
- DEC 17, 2018 Duke Research Blog
  
  A Chinese Scientist Gene-Edited a Human Embryo: What, How & Why
- OCT 3, 2018 Duke Med Alumni News
  
  From Innovation to Impact
- APR 27, 2018
  
  CRISPR/Cas9 Silences Gene Associated with High Cholesterol
- APR 26, 2018 Pratt School of Engineering
  
  Pratt Researchers Advance Treatment That Reduces Blood Cholesterol Levels in Adult Mice
- APR 9, 2018
  
  Faculty Startup Sold to Belgian Pharma for $30 Million
- NOV 29, 2017
  
  Two Postdocs Win Gene Therapy Fellowship
- APR 4, 2017 Pratt School of Engineering
  
  Screening the Human Genome's 'Dark Matter'
- APR 3, 2017 The Scientist
  
  CRISPR Screen Detects Functional Gene Regulation
- MAR 15, 2017 CNBC
  
  Betting on the first disease to be treated by gene editing
- MAY 5, 2016
  
  Duke Awards Distinguished Professorships, Inducts New Bass Society Members
- JAN 4, 2016 The New York Times
  
  Gene editing offers hope for treating Duchenne muscular dystrophy, studies find
- JAN 4, 2016 BBC News
  
  Gene editing treats disease in mice
- DEC 31, 2015
  
  CRISPR Treats Genetic Disorder in Adult Mammal
- OCT 27, 2015
  
  Pratt Research Brings Precise Control to Gene Expression
- MAY 26, 2015
  
  Studying the Harm and Healing Power of Steroids
- APR 6, 2015
  
  Engineers gain control of gene activity; new therapies may be ahead
- FEB 19, 2015
  
  Bacterial Defense Mechanism Targets Duchenne Muscular Dystrophy
- FEB 18, 2015
  
  Bacterial Defense Mechanism Targets Duchenne Muscular Dystrophy
- FEB 10, 2015
  
  Lighting Up the Duke 'D' With Genes
Awards & Honors
Research
Selected Grants
- Mechanotransduction in Meniscus Health and Repair awarded by National Institutes of Health 2019 - 2023
- Epigenomic Reprogramming in Patient Derived Models of Colorectal Cancer awarded by National Institutes of Health 2018 - 2023
- The Branched Chain Ketoacid Dehydrogenase Kinase-Phosphatase System as a New Regulatory Node in Myocardial Fuel Section awarded by National Institutes of Health 2018 - 2023
- Engineering Technologies to Determine Causal Relationships Between Chromatin Structure and Gene Regulation awarded by National Science Foundation 2018 - 2022
- Summer Scholars Program in Genome Sciences and Medicine awarded by National Institutes of Health 2017 - 2022
- Medical Scientist Training Program awarded by National Institutes of Health 1997 - 2022
- University Training Program in Biomolecular and Tissue Engineering awarded by National Institutes of Health 1994 - 2022
- Deciphering the regulation of gene expression in the etiology of LOAD awarded by National Institutes of Health 2017 - 2022
- Postdoctoral Training in Genomic Medicine Research awarded by National Institutes of Health 2017 - 2022
- Training Program in Developmental and Stem Cell Biology awarded by National Institutes of Health 2001 - 2022
- To support research on the development of CRISPR-based epigenome editing tools to refine genome wide association studies awarded by Open Philanthropy Project 2018 - 2021
- Evolving High Potency AAV Vectors for Neuromuscular Genome Editing awarded by National Institutes of Health 2018 - 2021
- Regulatory Mechanisms of CD4+ T Cell Differentiation awarded by National Institutes of Health 2017 - 2021
- Bioinformatics and Computational Biology Training Program awarded by National Institutes of Health 2005 - 2021
- CRISPR/Cas9-Based Gene Editing for the Correction of Duchenne Muscular Dystrophy awarded by National Institutes of Health 2016 - 2021
- In Vivo Epigenome Editing with CRISPR-Based Histone Acetyltransferase Transgenic Mice awarded by National Institutes of Health 2016 - 2021
- Designing a next generation vector for CRISPR/Cas9-mediated gene editing to treat Duchenne muscular dystrophy awarded by North Carolina Biotechnology Center 2018 - 2020
- Genome Editing For Duchenne Muscular Dystrophy awarded by Sarepta Therapeutics, Inc. 2017 - 2020
- Epigenome Editing Technologies to Control Diverse Biological Functions awarded by Allen Institute for Brain Science 2017 - 2020
- Collaborative Research: Adapting Cas9 Protein from CRISPR as a Structural Unit for Molecular Assembly awarded by National Science Foundation 2017 - 2020
- Functional characterization of regulatory variants associated with maternal hyperglycemia awarded by National Institutes of Health 2017 - 2020
- Non-viral delivery of CRISPR/Cas9 for targeted gene replacement awarded by National Institutes of Health 2018 - 2020
- REU Site for Meeting the Grand Challenges in Engineering awarded by National Science Foundation 2017 - 2020
- Developing Brain-penetrant G9a/GLP Inhibitors for Treating Prader-Willi Syndrome awarded by Levo Therapeutics, Inc 2018 - 2020
- Enhancing Neuronal Reprogramming with Epigenome Editing awarded by National Institutes of Health 2018 - 2020
- Enhancing Neuronal Reprogramming with Epigenome Editing awarded by National Institutes of Health 2017 - 2019
- Investigating Autophagy in GSD-Ia awarded by National Institutes of Health 2015 - 2019
- Development of AAV-Based Curative Therapies for Correcting Duchenne Muscular Dystrophy by Targeted Genomic Integration awarded by North Carolina Biotechnology Center 2017 - 2019
- An organotypic model recapitulating colon cancer microenvironment and metastasis awarded by Cleveland Clinic Foundation 2017 - 2019
- Treating Duchenne Cardiomyopathy in the Mouse Model by Gene Repair awarded by University of Missouri 2016 - 2019
- Combinatorial Biomimetic Systems for High-Throughput Manipulation of Genome-Edited Dystrophic Muscle Stem Cells awarded by Cornell University 2018 - 2019
- Systemic Inflammation in Microphysiological Models of Muscle and Vascular Disease awarded by National Institutes of Health 2017 - 2019
- Novel Approaches for Correcting Respiratory Insufficiency in Pompe Disease awarded by National Institutes of Health 2014 - 2019
- Reprogrammed autologous T cells to promote transplant tolerance awarded by Element Genomics, Inc. 2018 - 2019
- Systemic EGFRvIII-targeted bispecific antibody as immunotherapy for glioblastoma awarded by National Institutes of Health 2015 - 2019
- Defining the Mechanisms of Gene Regulation and Drug Resistance in Cancer awarded by Thorek Memorial Foundation 2017 - 2019
- Decoding and Reprogramming the Corticosteroid Transcriptional Regulatory Network awarded by National Institutes of Health 2015 - 2018
- Trans-regulatory mechanisms of glucocorticoid-mediated transcriptional repression awarded by National Institutes of Health 2016 - 2018
- Genome engineering for Duchenne muscular dystrophy awarded by American Heart Association 2017 - 2018
- Engineering Novel Genome Engineering Systems awarded by Locus Biosciences, Inc. 2016 - 2018
- Circulatory system and integrated muscle tissue for drug and tissue toxicity awarded by National Institutes of Health 2012 - 2018
- Engineering Targeted Epigenetic Modifiers for Precise Control of Gene Regulation awarded by National Institutes of Health 2013 - 2018
- A Platform Technology for High-Throughput Screening of Gene Regulatory Elements awarded by Element Genomics, Inc. 2016 - 2017
- Functional Tissue Engineering of Cartilage Using Induced Pluripotent Stem Cells awarded by National Institutes of Health 2015 - 2017
- MD140071 Multiplex CRISPR/Cas9-Based Genome Engineering for the Genetic Correction of Duchenne Muscular Dystrophy awarded by United States Army Medical Research and Materiel Command 2015 - 2017
- CRISPR/Cas9-based genome editing in mouse models of Duchenne muscular dystrophy awarded by Hartwell Foundation 2015 - 2017
- Scaffold-Mediated Gene Delivery for Engineering of Osteochondral Tissues awarded by National Institutes of Health 2015 - 2017
- Gertude B. Elion Mentored Medical Research Award awarded by Triangle Community Foundation 2016 - 2017
- Genome Editing of Stem Cells for Analysis of Osteoarthritis Causal Variants awarded by National Institutes of Health 2014 - 2017
- CAREER: Photoregulated Gene Expression for Spatiotemporal Control of Morphogenesis awarded by National Science Foundation 2012 - 2017
- Engineering Morphogenetic Factors for Enhanced Genetic Reprogramming awarded by National Institutes of Health 2011 - 2016
- Engineering New Biological Therapies for Arthritis awarded by Arthritis Foundation 2014 - 2015
- Live-Animal Micro-CT System awarded by National Institutes of Health 2012 - 2014
- Spatially Controlled Gene Delivery of Morphogenetic Factors from Woven Scaffolds awarded by National Institutes of Health 2011 - 2014
Publications & Artistic Works
Selected Publications
- Books
  - Holtzman, L, and Gersbach, CA. Editing the Epigenome: Reshaping the Genomic Landscape. August 2018. Full Text
- Academic Articles
  - Nelson, CE, Wu, Y, Gemberling, MP, Oliver, ML, Waller, MA, Bohning, JD, Robinson-Hamm, JN, Bulaklak, K, Castellanos Rivera, RM, Collier, JH, Asokan, A, and Gersbach, CA. "Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy." Nature Medicine 25, no. 3 (March 2019): 427-432. Full Text
  - Adkar, SS, Wu, C-L, Willard, VP, Dicks, A, Ettyreddy, A, Steward, N, Bhutani, N, Gersbach, CA, and Guilak, F. "Step-Wise Chondrogenesis of Human Induced Pluripotent Stem Cells and Purification Via a Reporter Allele Generated by CRISPR-Cas9 Genome Editing." Stem Cells (Dayton, Ohio) 37, no. 1 (January 2019): 65-76. Full Text
  - Chen, L-F, Lin, YT, Gallegos, DA, Hazlett, MF, Gómez-Schiavon, M, Yang, MG, Kalmeta, B, Zhou, AS, Holtzman, L, Gersbach, CA, Grandl, J, Buchler, NE, and West, AE. "Enhancer Histone Acetylation Modulates Transcriptional Bursting Dynamics of Neuronal Activity-Inducible Genes." Cell Reports 26, no. 5 (January 2019): 1174-1188.e5. Full Text
  - Black, JB, and Gersbach, CA. "Synthetic transcription factors for cell fate reprogramming." Current Opinion in Genetics & Development 52 (October 2018): 13-21. (Review) Full Text
  - Huynh, NPT, Brunger, JM, Gloss, CC, Moutos, FT, Gersbach, CA, and Guilak, F. "Genetic Engineering of Mesenchymal Stem Cells for Differential Matrix Deposition on 3D Woven Scaffolds." Tissue Engineering. Part A 24, no. 19-20 (October 2018): 1531-1544. Full Text
  - McDowell, IC, Barrera, A, D'Ippolito, AM, Vockley, CM, Hong, LK, Leichter, SM, Bartelt, LC, Majoros, WH, Song, L, Safi, A, Koçak, DD, Gersbach, CA, Hartemink, AJ, Crawford, GE, Engelhardt, BE, and Reddy, TE. "Glucocorticoid receptor recruits to enhancers and drives activation by motif-directed binding." Genome Res 28, no. 9 (September 2018): 1272-1284. Full Text Link to Item
  - D'Ippolito, AM, McDowell, IC, Barrera, A, Hong, LK, Leichter, SM, Bartelt, LC, Vockley, CM, Majoros, WH, Safi, A, Song, L, Gersbach, CA, Crawford, GE, and Reddy, TE. "Pre-established Chromatin Interactions Mediate the Genomic Response to Glucocorticoids." Cell Systems 7, no. 2 (August 2018): 146-160.e7. Full Text
  - Klann, TS, Black, JB, and Gersbach, CA. "CRISPR-based methods for high-throughput annotation of regulatory DNA." Current Opinion in Biotechnology 52 (August 2018): 32-41. (Review) Full Text
  - Kocak, DD, and Gersbach, CA. "From CRISPR scissors to virus sensors." Nature 557, no. 7704 (May 2018): 168-169. (Letter) Full Text
  - Thakore, PI, Kwon, JB, Nelson, CE, Rouse, DC, Gemberling, MP, Oliver, ML, and Gersbach, CA. "RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors." Nature Communications 9, no. 1 (April 26, 2018): 1674-null. Full Text
  - Gersbach, CA, and Barrangou, R. "Pulling the genome in opposite directions to dissect gene networks." Genome Biology 19, no. 1 (March 26, 2018). Full Text
  - Pickar, AK, and Gersbach, CA. "Gene therapies for hemophilia hit the mark in clinical trials." Nature Medicine 24, no. 2 (February 7, 2018): 121-122. Full Text
  - Gemberling, M, and Gersbach, CA. "Boosting, Not Breaking: CRISPR Activators Treat Disease Models." Molecular Therapy : the Journal of the American Society of Gene Therapy 26, no. 2 (February 2018): 334-336. Full Text
  - Klann, TS, Crawford, GE, Reddy, TE, and Gersbach, CA. "Screening Regulatory Element Function with CRISPR/Cas9-based Epigenome Editing." Methods in Molecular Biology (Clifton, N.J.) 1767 (January 2018): 447-480. Full Text
  - Manandhar, D, Song, L, Kabadi, A, Kwon, JB, Edsall, LE, Ehrlich, M, Tsumagari, K, Gersbach, CA, Crawford, GE, and Gordân, R. "Incomplete MyoD-induced transdifferentiation is associated with chromatin remodeling deficiencies." Nucleic Acids Research 45, no. 20 (November 2017): 11684-11699. Full Text
  - Nelson, CE, Robinson-Hamm, JN, and Gersbach, CA. "Genome engineering: A new approach to gene therapy for neuromuscular disorders." Nature Reviews Neurology 13, no. 11 (November 1, 2017): 647-661. (Review) Full Text
  - Pathak, GP, Spiltoir, JI, Höglund, C, Polstein, LR, Heine-Koskinen, S, Gersbach, CA, Rossi, J, and Tucker, CL. "Bidirectional approaches for optogenetic regulation of gene expression in mammalian cells using Arabidopsis cryptochrome 2." Nucleic Acids Research 45, no. 20 (November 2017): e167-null. Full Text
  - Polstein, LR, Juhas, M, Hanna, G, Bursac, N, and Gersbach, CA. "An Engineered Optogenetic Switch for Spatiotemporal Control of Gene Expression, Cell Differentiation, and Tissue Morphogenesis." Acs Synthetic Biology 6, no. 11 (November 2017): 2003-2013. Full Text
  - Adkar, SS, Brunger, JM, Willard, VP, Wu, C-L, Gersbach, CA, and Guilak, F. "Genome Engineering for Personalized Arthritis Therapeutics." Trends in molecular medicine 23, no. 10 (October 2017): 917-931. (Review) Full Text
  - Farhang, N, Brunger, JM, Stover, JD, Thakore, PI, Lawrence, B, Guilak, F, Gersbach, CA, Setton, LA, and Bowles, RD. "* CRISPR-Based Epigenome Editing of Cytokine Receptors for the Promotion of Cell Survival and Tissue Deposition in Inflammatory Environments." Tissue Engineering. Part A 23, no. 15-16 (August 2017): 738-749. Full Text
  - Huang, J, Chen, M, Whitley, MJ, Kuo, H-C, Xu, ES, Walens, A, Mowery, YM, Van Mater, D, Eward, WC, Cardona, DM, Luo, L, Ma, Y, Lopez, OM, Nelson, CE, Robinson-Hamm, JN, Reddy, A, Dave, SS, Gersbach, CA, Dodd, RD, and Kirsch, DG. "Generation and comparison of CRISPR-Cas9 and Cre-mediated genetically engineered mouse models of sarcoma." Nature Communications 8 (July 10, 2017): 15999-null. Full Text
  - Black, JB, Perez-Pinera, P, and Gersbach, CA. "Mammalian Synthetic Biology: Engineering Biological Systems." Annual Review of Biomedical Engineering 19 (June 2017): 249-277. (Review) Full Text
  - Klann, TS, Black, JB, Chellappan, M, Safi, A, Song, L, Hilton, IB, Crawford, GE, Reddy, TE, and Gersbach, CA. "CRISPR-Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome." Nature Biotechnology 35, no. 6 (June 2017): 561-568. Full Text
  - Brunger, JM, Zutshi, A, Willard, VP, Gersbach, CA, and Guilak, F. "CRISPR/Cas9 Editing of Murine Induced Pluripotent Stem Cells for Engineering Inflammation-Resistant Tissues." Arthritis & rheumatology (Hoboken, N.J.) 69, no. 5 (May 2017): 1111-1121. Full Text
  - Brunger, JM, Zutshi, A, Willard, VP, Gersbach, CA, and Guilak, F. "Genome Engineering of Stem Cells for Autonomously Regulated, Closed-Loop Delivery of Biologic Drugs." Stem Cell Reports 8, no. 5 (May 2017): 1202-1213. Full Text
  - Barrangou, R, and Gersbach, CA. "Expanding the CRISPR Toolbox: Targeting RNA with Cas13b." Molecular cell 65, no. 4 (February 2017): 582-584. Full Text
  - Hilton, IB, and Gersbach, CA. "Genetic engineering: Chemical control for CRISPR editing." Nature Chemical Biology 13, no. 1 (January 1, 2017): 2-3. Full Text
  - Housden, BE, Muhar, M, Gemberling, M, Gersbach, CA, Stainier, DYR, Seydoux, G, Mohr, SE, Zuber, J, and Perrimon, N. "Loss-of-function genetic tools for animal models: cross-species and cross-platform differences." Nature Reviews. Genetics 18, no. 1 (January 2017): 24-40. (Review) Full Text
  - Black, JB, Adler, AF, Wang, H-G, D'Ippolito, AM, Hutchinson, HA, Reddy, TE, Pitt, GS, Leong, KW, and Gersbach, CA. "Targeted Epigenetic Remodeling of Endogenous Loci by CRISPR/Cas9-Based Transcriptional Activators Directly Converts Fibroblasts to Neuronal Cells." Cell Stem Cell 19, no. 3 (September 2016): 406-414. Full Text
  - Lee, J, Xu, L, Gibson, TM, Gersbach, CA, and Sullenger, BA. "Differential effects of toll-like receptor stimulation on mRNA-driven myogenic conversion of human and mouse fibroblasts." Biochemical and Biophysical Research Communications 478, no. 3 (September 2016): 1484-1490. Full Text
  - Robinson-Hamm, JN, and Gersbach, CA. "Gene therapies that restore dystrophin expression for the treatment of Duchenne muscular dystrophy." Human Genetics 135, no. 9 (September 2016): 1029-1040. (Review) Full Text
  - Moutos, FT, Glass, KA, Compton, SA, Ross, AK, Gersbach, CA, Guilak, F, and Estes, BT. "Anatomically shaped tissue-engineered cartilage with tunable and inducible anticytokine delivery for biological joint resurfacing." Proceedings of the National Academy of Sciences of the United States of America 113, no. 31 (August 2016): E4513-E4522. Full Text
  - Hwang, PY, Jing, L, Chen, J, Lim, F-L, Tang, R, Choi, H, Cheung, KM, Risbud, MV, Gersbach, CA, Guilak, F, Leung, VY, and Setton, LA. "N-cadherin is Key to Expression of the Nucleus Pulposus Cell Phenotype under Selective Substrate Culture Conditions." Scientific reports 6 (June 13, 2016): 28038-. Full Text
  - Nelson, CE, and Gersbach, CA. "Engineering Delivery Vehicles for Genome Editing." Annual review of chemical and biomolecular engineering 7 (June 2016): 637-662. (Review) Full Text
  - Landau, DJ, Brooks, ED, Perez-Pinera, P, Amarasekara, H, Mefferd, A, Li, S, Bird, A, Gersbach, CA, and Koeberl, DD. "In Vivo Zinc Finger Nuclease-mediated Targeted Integration of a Glucose-6-phosphatase Transgene Promotes Survival in Mice With Glycogen Storage Disease Type IA." Molecular Therapy : the Journal of the American Society of Gene Therapy 24, no. 4 (April 2016): 697-706. Full Text
  - Josephs, EA, Kocak, DD, Fitzgibbon, CJ, McMenemy, J, Gersbach, CA, and Marszalek, PE. "Structure and specificity of the RNA-guided endonuclease Cas9 during DNA interrogation, target binding and cleavage." Nucleic Acids Research 44, no. 5 (March 2016): 2474-null. Full Text
  - Maeder, ML, and Gersbach, CA. "Genome-editing Technologies for Gene and Cell Therapy." Molecular Therapy : the Journal of the American Society of Gene Therapy 24, no. 3 (March 2016): 430-446. (Review) Full Text
  - Nelson, CE, and Gersbach, CA. "Cas9 loosens its grip on off-target sites." Nature Biotechnology 34, no. 3 (March 2016): 298-299. Full Text
  - Thakore, PI, Black, JB, Hilton, IB, and Gersbach, CA. "Editing the epigenome: technologies for programmable transcription and epigenetic modulation." Nature Methods 13, no. 2 (February 2016): 127-137. (Review) Full Text
  - Nelson, CE, Hakim, CH, Ousterout, DG, Thakore, PI, Moreb, EA, Castellanos Rivera, RM, Madhavan, S, Pan, X, Ran, FA, Yan, WX, Asokan, A, Zhang, F, Duan, D, and Gersbach, CA. "In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy." Science (New York, N.Y.) 351, no. 6271 (January 2016): 403-407. Full Text
  - Ousterout, DG, and Gersbach, CA. "The Development of TALE Nucleases for Biotechnology." Methods in molecular biology (Clifton, N.J.) 1338 (January 2016): 27-42. Full Text
  - Thakore, PI, and Gersbach, CA. "Design, Assembly, and Characterization of TALE-Based Transcriptional Activators and Repressors." Methods in molecular biology (Clifton, N.J.) 1338 (January 2016): 71-88. Full Text
  - Doudna, JA, and Gersbach, CA. "Genome editing: the end of the beginning." Genome biology 16 (December 23, 2015): 292-. Full Text
  - Thakore, PI, D'Ippolito, AM, Song, L, Safi, A, Shivakumar, NK, Kabadi, AM, Reddy, TE, Crawford, GE, and Gersbach, CA. "Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements." Nature Methods 12, no. 12 (December 2015): 1143-1149. Full Text
  - Hilton, IB, and Gersbach, CA. "Enabling functional genomics with genome engineering." Genome Research 25, no. 10 (October 2015): 1442-1455. (Review) Full Text
  - Josephs, EA, Kocak, DD, Fitzgibbon, CJ, McMenemy, J, Gersbach, CA, and Marszalek, PE. "Structure and specificity of the RNA-guided endonuclease Cas9 during DNA interrogation, target binding and cleavage." Nucleic acids research 43, no. 18 (October 2015): 8924-8941. Full Text
  - Polstein, LR, Perez-Pinera, P, Kocak, DD, Vockley, CM, Bledsoe, P, Song, L, Safi, A, Crawford, GE, Reddy, TE, and Gersbach, CA. "Genome-wide specificity of DNA binding, gene regulation, and chromatin remodeling by TALE- and CRISPR/Cas9-based transcriptional activators." Genome Research 25, no. 8 (August 2015): 1158-1169. Full Text
  - Polstein, LR, Perez-Pinera, P, Kocak, DD, Vockley, CM, Bledsoe, P, Song, L, Safi, A, Crawford, GE, Reddy, TE, and Gersbach, CA. "Genome-wide specificity of DNA binding, gene regulation, and chromatin remodeling by TALE- and CRISPR/Cas9-based transcriptional activators." GENOME RESEARCH 25, no. 8 (August 2015): 1158-1169. Full Text Link to Item
  - Gibson, TM, and Gersbach, CA. "Single-molecule analysis of myocyte differentiation reveals bimodal lineage commitment." Integrative biology : quantitative biosciences from nano to macro 7, no. 6 (June 2015): 663-671. Full Text
  - Kabadi, AM, Thakore, PI, Vockley, CM, Ousterout, DG, Gibson, TM, Guilak, F, Reddy, TE, and Gersbach, CA. "Enhanced MyoD-induced transdifferentiation to a myogenic lineage by fusion to a potent transactivation domain." Acs Synthetic Biology 4, no. 6 (June 2015): 689-699. Full Text
  - Frank, CL, Liu, F, Wijayatunge, R, Song, L, Biegler, MT, Yang, MG, Vockley, CM, Safi, A, Gersbach, CA, Crawford, GE, and West, AE. "Regulation of chromatin accessibility and Zic binding at enhancers in the developing cerebellum." Nature Neuroscience 18, no. 5 (May 2015): 647-656. Full Text
  - Hilton, IB, D'Ippolito, AM, Vockley, CM, Thakore, PI, Crawford, GE, Reddy, TE, and Gersbach, CA. "Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers." Nature Biotechnology 33, no. 5 (May 2015): 510-517. Full Text
  - Diekman, BO, Thakore, PI, O'Connor, SK, Willard, VP, Brunger, JM, Christoforou, N, Leong, KW, Gersbach, CA, and Guilak, F. "Knockdown of the cell cycle inhibitor p21 enhances cartilage formation by induced pluripotent stem cells." Tissue engineering. Part A 21, no. 7-8 (April 2015): 1261-1274. Full Text
  - Ousterout, DG, Kabadi, AM, Thakore, PI, Perez-Pinera, P, Brown, MT, Majoros, WH, Reddy, TE, and Gersbach, CA. "Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases." Molecular Therapy 23, no. 3 (March 5, 2015): 523-532. Full Text
  - Ousterout, DG, Kabadi, AM, Thakore, PI, Perez-Pinera, P, Brown, MT, Majoros, WH, Reddy, TE, and Gersbach, CA. "Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases." Molecular therapy : the journal of the American Society of Gene Therapy 23, no. 3 (March 2015): 523-532. Full Text
  - Ousterout, DG, Kabadi, AM, Thakore, PI, Perez-Pinera, P, Brown, MT, Majoros, WH, Reddy, TE, and Gersbach, CA. "Correction of Dystrophin Expression in Cells From Duchenne Muscular Dystrophy Patients Through Genomic Excision of Exon 51 by Zinc Finger Nucleases." MOLECULAR THERAPY 23, no. 3 (March 2015): 523-532. Full Text Link to Item
  - Polstein, LR, and Gersbach, CA. "A light-inducible CRISPR-Cas9 system for control of endogenous gene activation." Nature Chemical Biology 11, no. 3 (March 2015): 198-200. Full Text
  - Ousterout, DG, Kabadi, AM, Thakore, PI, Majoros, WH, Reddy, TE, and Gersbach, CA. "Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy." Nature Communications 6 (February 18, 2015): 6244-null. Full Text
  - Polstein, LR, and Gersbach, CA. "A light-inducible CRISPR-Cas9 system for control of endogenous gene activation." Nature Chemical Biology 11, no. 3 (January 1, 2015): 198-200. Full Text
  - Chakraborty, S, Ji, H, Chen, J, Gersbach, CA, and Leong, KW. "Vector modifications to eliminate transposase expression following piggyBac-mediated transgenesis." Scientific reports 4 (December 10, 2014): 7403-. Full Text
  - Chakraborty, S, Ji, H, Kabadi, AM, Gersbach, CA, Christoforou, N, and Leong, KW. "A CRISPR/Cas9-based system for reprogramming cell lineage specification." Stem Cell Reports 3, no. 6 (December 2014): 940-947. Full Text
  - Gersbach, CA. "Genome engineering: the next genomic revolution." Nature Methods 11, no. 10 (October 2014): 1009-1011. Full Text
  - Kabadi, AM, Ousterout, DG, Hilton, IB, and Gersbach, CA. "Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector." Nucleic Acids Research 42, no. 19 (October 2014): e147-null. Full Text
  - Kabadi, AM, and Gersbach, CA. "Special issue on engineered DNA-binding proteins." Acs Synthetic Biology 3, no. 10 (October 2014): 702-703. Full Text
  - Kabadi, AM, and Gersbach, CA. "Engineering synthetic TALE and CRISPR/Cas9 transcription factors for regulating gene expression." Methods (San Diego, Calif.) 69, no. 2 (September 2014): 188-197. Full Text
  - Gersbach, CA, Gaj, T, and Barbas, CF. "Synthetic zinc finger proteins: the advent of targeted gene regulation and genome modification technologies." Accounts of Chemical Research 47, no. 8 (August 2014): 2309-2318. Full Text
  - Gersbach, CA, and Perez-Pinera, P. "Activating human genes with zinc finger proteins, transcription activator-like effectors and CRISPR/Cas9 for gene therapy and regenerative medicine." Expert opinion on therapeutic targets 18, no. 8 (August 2014): 835-839. Full Text
  - Glass, KA, Link, JM, Brunger, JM, Moutos, FT, Gersbach, CA, and Guilak, F. "Tissue-engineered cartilage with inducible and tunable immunomodulatory properties." Biomaterials 35, no. 22 (July 2014): 5921-5931. Full Text
  - High, K, Gregory, PD, and Gersbach, C. "CRISPR technology for gene therapy." Nature Medicine 20, no. 5 (May 2014): 476-477. Full Text
  - Brunger, JM, Huynh, NPT, Guenther, CM, Perez-Pinera, P, Moutos, FT, Sanchez-Adams, J, Gersbach, CA, and Guilak, F. "Scaffold-mediated lentiviral transduction for functional tissue engineering of cartilage." Proceedings of the National Academy of Sciences of the United States of America 111, no. 9 (March 2014): E798-E806. Full Text
  - Gersbach, CA, Gaj, T, and Barbas, CF. "Comparing genome editing technologies." Genetic Engineering and Biotechnology News 34, no. 5 (March 1, 2014). Full Text
  - "Tissue-engineered cartilage with inducible and tunable immunomodulatory properties." Biomaterials 35, no. 22 (January 1, 2014): 5921-5931. Full Text
  - Kabadi, AM, and Gersbach, CA. "Engineering synthetic TALE and CRISPR/Cas9 transcription factors for regulating gene expression." Methods 69, no. 2 (January 1, 2014): 188-197. Full Text
  - Polstein, LR, and Gersbach, CA. "Light-inducible gene regulation with engineered zinc finger proteins." Methods in Molecular Biology (Clifton, N.J.) 1148 (January 2014): 89-107. Full Text
  - "Corrigendum: Reading Frame Correction by Targeted Genome Editing Restores Dystrophin Expression in Cells From Duchenne Muscular Dystrophy Patients." Molecular Therapy 21, no. 11 (November 2013): 2130-2130. Full Text
  - Duvall, CL, Prokop, A, Gersbach, CA, and Davidson, JM. "Gene Delivery into Cells and Tissues." (November 1, 2013): 687-723. (Chapter) Full Text
  - Perez-Pinera, P, Kocak, DD, Vockley, CM, Adler, AF, Kabadi, AM, Polstein, LR, Thakore, PI, Glass, KA, Ousterout, DG, Leong, KW, Guilak, F, Crawford, GE, Reddy, TE, and Gersbach, CA. "RNA-guided gene activation by CRISPR-Cas9-based transcription factors." Nat Methods 10, no. 10 (October 2013): 973-976. Full Text Link to Item
  - Ousterout, DG, Perez-Pinera, P, Thakore, PI, Kabadi, AM, Brown, MT, Qin, X, Fedrigo, O, Mouly, V, Tremblay, JP, and Gersbach, CA. "Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients." Molecular Therapy : the Journal of the American Society of Gene Therapy 21, no. 9 (September 2013): 1718-1726. Full Text
  - Gaj, T, Gersbach, CA, and Barbas, CF. "ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering." Trends in Biotechnology 31, no. 7 (July 2013): 397-405. (Review) Full Text
  - Dumbauld, DW, Lee, TT, Singh, A, Scrimgeour, J, Gersbach, CA, Zamir, EA, Fu, J, Chen, CS, Curtis, JE, Craig, SW, and García, AJ. "How vinculin regulates force transmission." Proceedings of the National Academy of Sciences of the United States of America 110, no. 24 (June 2013): 9788-9793. Full Text
  - Gibson, TM, and Gersbach, CA. "The role of single-cell analyses in understanding cell lineage commitment." Biotechnol J 8, no. 4 (April 2013): 397-407. (Review) Full Text Link to Item
  - Bhakta, MS, Henry, IM, Ousterout, DG, Das, KT, Lockwood, SH, Meckler, JF, Wallen, MC, Zykovich, A, Yu, Y, Leo, H, Xu, L, Gersbach, CA, and Segal, DJ. "Highly active zinc-finger nucleases by extended modular assembly." Genome Research 23, no. 3 (March 2013): 530-538. Full Text
  - Perez-Pinera, P, Ousterout, DG, Brunger, JM, Farin, AM, Glass, KA, Guilak, F, Crawford, GE, Hartemink, AJ, and Gersbach, CA. "Synergistic and tunable human gene activation by combinations of synthetic transcription factors." Nature Methods 10, no. 3 (March 2013): 239-242. Full Text
  - Tremblay, JP, Xiao, X, Aartsma-Rus, A, Barbas, C, Blau, HM, Bogdanove, AJ, Boycott, K, Braun, S, Breakefield, XO, Bueren, JA, Buschmann, M, Byrne, BJ, Calos, M, Cathomen, T, Chamberlain, J, Chuah, M, Cornetta, K, Davies, KE, Dickson, JG, Duchateau, P, Flotte, TR, Gaudet, D, Gersbach, CA, Gilbert, R, Glorioso, J, Herzog, RW, High, KA, Huang, W, Huard, J, Joung, JK, Liu, D, Liu, D, Lochmüller, H, Lustig, L, Martens, J, Massie, B, Mavilio, F, Mendell, JR, Nathwani, A, Ponder, K, Porteus, M, Puymirat, J, Samulski, J, Takeda, S, Thrasher, A, VandenDriessche, T, Wei, Y, Wilson, JM, Wilton, SD, Wolfe, JH, and Gao, G. "Translating the genomics revolution: the need for an international gene therapy consortium for monogenic diseases." Molecular Therapy : the Journal of the American Society of Gene Therapy 21, no. 2 (February 2013): 266-268. (Letter) Full Text
  - Gaj, T, Gersbach, CA, and Barbas, CF. "ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering." Trends in Biotechnology 31, no. 7 (2013): 397-405. Full Text
  - Gersbach, CA, and Barbas, CF. "Targeted plasmid integration into the Human Genome by engineered recombinases." Topics in Current Genetics 23 (January 1, 2013): 267-284. Full Text
  - Gersbach, CA. "Engineered Proteins for Controlling Gene Expression." (2013): 125-138. Full Text
  - Gibson, TM, and Gersbach, CA. "The role of single-cell analyses in understanding cell lineage commitment." Biotechnology Journal 8, no. 4 (2013): 397-407. Full Text
  - Ousterout, DG, Perez-Pinera, P, Thakore, PI, Kabadi, AM, Brown, MT, Qin, X, Fedrigo, O, Mouly, V, Tremblay, JP, and Gersbach, CA. "Reading frame correction by targeted genome editing restores dystrophin expression in cells from duchenne muscular dystrophy patients." Molecular Therapy 21, no. 9 (2013): 1718-1726. Full Text
  - Perez-Pinera, P, Kocak, DD, Vockley, CM, Adler, AF, Kabadi, AM, Polstein, LR, Thakore, PI, Glass, KA, Ousterout, DG, Leong, KW, Guilak, F, Crawford, GE, Reddy, TE, and Gersbach, CA. "RNA-guided gene activation by CRISPR-Cas9-based transcription factors." Nature Methods 10, no. 10 (2013): 973-976. Full Text
  - Polstein, LR, and Gersbach, CA. "Light-inducible spatiotemporal control of gene activation by customizable zinc finger transcription factors." Journal of the American Chemical Society 134, no. 40 (October 2012): 16480-16483. Full Text
  - Perez-Pinera, P, Ousterout, DG, and Gersbach, CA. "Advances in targeted genome editing." Current Opinion in Chemical Biology 16, no. 3-4 (August 2012): 268-277. (Review) Full Text
  - Polstein, LR, and Gersbach, CA. "Photoregulated Gene Expression in Human Cells With Light-Inducible Engineered Transcription Factors." Asme 2012 Summer Bioengineering Conference, Parts a and B (June 20, 2012). Full Text
  - Perez-Pinera, P, Ousterout, DG, Brown, MT, and Gersbach, CA. "Gene targeting to the ROSA26 locus directed by engineered zinc finger nucleases." Nucleic Acids Res 40, no. 8 (April 2012): 3741-3752. Full Text Link to Item
  - "Engineered bioactive molecules." 5 (October 1, 2011): 131-145. (Chapter)
  - Gersbach, CA, Gaj, T, Gordley, RM, Mercer, AC, and Barbas, CF. "Targeted plasmid integration into the human genome by an engineered zinc-finger recombinase." Nucleic Acids Research 39, no. 17 (September 2011): 7868-7878. Full Text
  - Gaj, T, Mercer, AC, Gersbach, CA, Gordley, RM, and Barbas, CF. "Structure-guided reprogramming of serine recombinase DNA sequence specificity." Proceedings of the National Academy of Sciences of the United States of America 108, no. 2 (January 11, 2011): 510-515. Full Text
  - Gaj, T, Mercer, AC, Gersbach, CA, Gordley, RM, and Barbas, CF. "Structure-guided reprogramming of serine recombinase DNA sequence specificity." Proceedings of the National Academy of Sciences of the United States of America 108, no. 2 (January 2011): 498-503. Full Text
  - Gersbach, CA. "Engineered Proteins for Controlling Gene Expression." (2011): 159-176. Full Text
  - Gersbach, CA, Gaj, T, Gordley, RM, and Barbas, CF. "Directed evolution of recombinase specificity by split gene reassembly." Nucleic Acids Res 38, no. 12 (July 2010): 4198-4206. Full Text Link to Item
  - Gordley, RM, Gersbach, CA, and Barbas, CF. "Synthesis of programmable integrases." Proc Natl Acad Sci U S A 106, no. 13 (March 31, 2009): 5053-5058. Full Text Link to Item
  - Pregizer, S, Barski, A, Gersbach, CA, García, AJ, and Frenkel, B. "Identification of novel Runx2 targets in osteoblasts: cell type-specific BMP-dependent regulation of Tram2." J Cell Biochem 102, no. 6 (December 15, 2007): 1458-1471. Full Text Link to Item
  - Gersbach, CA, Coyer, SR, Le Doux, JM, and García, AJ. "Biomaterial-mediated retroviral gene transfer using self-assembled monolayers." Biomaterials 28, no. 34 (December 2007): 5121-5127. Full Text Link to Item
  - Gersbach, CA, Guldberg, RE, and García, AJ. "In vitro and in vivo osteoblastic differentiation of BMP-2- and Runx2-engineered skeletal myoblasts." J Cell Biochem 100, no. 5 (April 1, 2007): 1324-1336. Full Text Link to Item
  - Gersbach, CA, Phillips, JE, and García, AJ. "Genetic engineering for skeletal regenerative medicine." Annu Rev Biomed Eng 9 (2007): 87-119. (Review) Full Text Link to Item
  - Phillips, JE, Gersbach, CA, and García, AJ. "Virus-based gene therapy strategies for bone regeneration." Biomaterials 28, no. 2 (January 2007): 211-229. (Review) Full Text
  - Gersbach, CA, Le Doux, JM, Guldberg, RE, and García, AJ. "Inducible regulation of Runx2-stimulated osteogenesis." Gene Ther 13, no. 11 (June 2006): 873-882. Full Text Link to Item
  - Phillips, JE, Gersbach, CA, Wojtowicz, AM, and García, AJ. "Glucocorticoid-induced osteogenesis is negatively regulated by Runx2/Cbfa1 serine phosphorylation." J Cell Sci 119, no. Pt 3 (February 1, 2006): 581-591. Full Text Link to Item
  - Gersbach, CA, Phillips, JE, Guldberg, RE, and García, AJ. "Runx2-genetically engineered cells for bone tissue engineering." Proceedings of the 2005 Summer Bioengineering Conference 2005 (December 1, 2005): 603-604.
  - Lan, MA, Gersbach, CA, Michael, KE, Keselowsky, BG, and García, AJ. "Myoblast proliferation and differentiation on fibronectin-coated self assembled monolayers presenting different surface chemistries." Biomaterials 26, no. 22 (August 2005): 4523-4531. Full Text Link to Item
  - Drevs, J, Zirrgiebel, U, Schmidt-Gersbach, CIM, Mross, K, Medinger, M, Lee, L, Pinheiro, J, Wood, J, Thomas, AL, Unger, C, Henry, A, Steward, WP, Laurent, D, Lebwohl, D, Dugan, M, and Marmé, D. "Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials." Annals of Oncology 16, no. 4 (April 1, 2005): 558-565. Full Text
  - Gersbach, CA, Byers, BA, Guldberg, RE, Pavlath, GK, and Garcia, AJ. "Runx2-stimulated transdifferentiation of primary skeletal myoblasts into an osteoblastic mineralizing phenotype for bone tissue engineering." Transactions 7th World Biomaterials Congress (December 1, 2004): 328-null.
  - Gersbach, CA, Byers, BA, Pavlath, GK, Guldberg, RE, and García, AJ. "Runx2/Cbfa1-genetically engineered skeletal myoblasts mineralize collagen scaffolds in vitro." Biotechnol Bioeng 88, no. 3 (November 5, 2004): 369-378. Full Text Link to Item
  - Gersbach, CA, Byers, BA, Pavlath, GK, and García, AJ. "Runx2/Cbfa1 stimulates transdifferentiation of primary skeletal myoblasts into a mineralizing osteoblastic phenotype." Exp Cell Res 300, no. 2 (November 1, 2004): 406-417. Full Text Link to Item
  - GERSBACH, CA. "Runx2/Cbfa1 stimulates transdifferentiation of primary skeletal myoblasts into a mineralizing osteoblastic phenotype." Exp. Cell Res. 300 (2004): 406-417.
  - García, AJ, Guldberg, RE, Byers, BA, Gersbach, CA, and Phillips, JE. "Addressing cell-sourcing limitations with gene therapy." IEEE Eng Med Biol Mag 22, no. 5 (September 2003): 65-70. Link to Item
- Book Sections
  - Thakore, PI, and Gersbach, CA. "Genome Engineering for Therapeutic Applications." In Translating Gene Therapy to the Clinic: Techniques and Approaches, 27-43. November 17, 2014. Full Text
  - Polstein, LR, and Gersbach, CA. "Spatiotemporal genetic control of cellular systems." In Tissue and Organ Regeneration: Advances in Micro- and Nanotechnology, 156-197. April 30, 2014. Full Text
- Conference Papers
  - Farhang, N, Brunger, JM, Stover, JD, Thakore, PI, Lawrence, BD, Guilak, F, Gersbach, CA, Setton, LA, and Bowles, RD. "CRISPRi Immunomodulation for Tissue Engineering/Stem Cell Therapies Targeting Intervertebral Disc Degeneration." September 1, 2015. Link to Item
  - Glass, KA, Ross, AK, Compton, SA, Gersbach, CA, Moutos, FT, Estes, BT, and Guilak, F. "Anatomically-Shaped Tissue-Engineered Cartilage with Tunable and Inducible Anti-Inflammatory Capabilities." September 1, 2015. Link to Item
  - Black, J, Adler, A, Hutchinson, H, Wang, H, Pitt, G, Leong, K, and Gersbach, C. "59. Multiplex Gene Activation by CRISPR/Cas9-Based Transcription Factors for the Direct Conversion of Fibroblasts to a Neuronal Phenotype." May 2015. Full Text
  - Schulz, E, Bergmann, T, Gebbing, M, Schildgen, V, Schildgen, O, Gersbach, C, and Ehrhardt, A. "Mutation Detection Following Non-Homologous End Joining (NHEJ): A Comparison of Different Semi Quantitative and Quantitative Methods." May 2014. Link to Item
  - Perez-Pinera, P, Ousterout, DG, Brunger, JM, Farin, AM, Glass, KA, Guilak, F, Crawford, GE, Hartemink, AJ, and Gersbach, CA. "Synergistic and Tunable Gene Activation by Combinations of Synthetic Transcription Factors." June 2013. Link to Item
  - Glass, KA, Brunger, JM, Gersbach, CA, and Guilak, F. "Tunable expression of IL-1Ra in genetically modified mesenchymal stem cells for cartilage tissue engineering." : Elsevier BV, April 2013. Full Text
Teaching & Mentoring
Recent Courses
Scholarly, Clinical, & Service Activities
Outreach & Engaged Scholarship

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Duke Appointment History

In the News

Awards & Honors

Selected Grants

Selected Publications

Books

Academic Articles

Book Sections

Conference Papers

Recent Courses

Outreach & Engaged Scholarship